breast cancer


    Tucatinib and Trastuzumab Deruxtecan Show Promise in HER2+ Breast Cancer

    Smruti Vidwans, PhD

    In 1998, the U.S. Food and Drug Administration (FDA) approved the drug trastuzumab (brand name Herceptin) for people with HER2-positive metastatic breast cancer. Overnight, HER2+ metastatic breast cancer became treatable (though not curable). Subsequent successful clinical studies led to use of trastuzumab earlier in the breast cancer journey—after surgery—to help prevent recurrence, as well as in earlier-stage HER2+ breast cancer. Meanwhile, the FDA approved… Read more »

  •   George Lundberg, MD

    Curated by Editor in Chief George Lundberg, MD, who notes:

    Breast cancer is the most common potentially lethal cancer diagnosed among American women. The great majority are cured, but that does not mean that the topic is without disagreements. To learn more, read this authoritative, up-to-date, detailed presentation from Medscape.